These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
89 related items for PubMed ID: 12055032
41. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, Boggian K, Chave JP, Bernasconi E, Egger M, Opravil M, Rickenbach M, Francioli P, Telenti A. Clin Infect Dis; 2001 Dec 01; 33(11):1931-7. PubMed ID: 11692306 [Abstract] [Full Text] [Related]
42. ddI, d4T, Hydroxyurea: new pancreatitis warning. AIDS Treat News; 1999 Nov 19; (No 331):1-3. PubMed ID: 11367125 [Abstract] [Full Text] [Related]
43. The role of nucleoside reverse transcriptase inhibitors usage in the incidence of hyperlactatemia and lactic acidosis in HIV/AIDS patients. Dragovic G, Jevtovic D. Biomed Pharmacother; 2012 Jun 19; 66(4):308-11. PubMed ID: 22658063 [Abstract] [Full Text] [Related]
44. [Fatal lactic acidosis in a patient with acquired immunodeficiency syndrome treated with highly active antiretroviral therapy. Report of a case]. Lasso M, Pérez J, Noriega LM, Northland R. Rev Med Chil; 2000 Oct 19; 128(10):1139-43. PubMed ID: 11349514 [Abstract] [Full Text] [Related]
45. [Neuromuscular diseases associated with HIV-1 infection]. Mukai E. No To Shinkei; 2004 Apr 19; 56(4):318-25. PubMed ID: 15237723 [No Abstract] [Full Text] [Related]
46. Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study. Osler M, Stead D, Rebe K, Meintjes G, Boulle A. HIV Med; 2010 Feb 19; 11(2):121-9. PubMed ID: 19702629 [Abstract] [Full Text] [Related]
47. FDA issues labeling changes for efavirenz. González-Lahoz J. AIDS Rev; 2004 Feb 19; 6(3):181-2. PubMed ID: 15595435 [No Abstract] [Full Text] [Related]
48. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression. Saez-Llorens X, Castaño E, Rathore M, Church J, Deville J, Gaur A, Estripeaut D, White K, Arterburn S, Enejosa JV, Cheng AK, Chuck SL, Rhee MS. Pediatr Infect Dis J; 2015 Apr 19; 34(4):376-82. PubMed ID: 25760565 [Abstract] [Full Text] [Related]
49. Side effects. FDA issues warning about d4T and ddI during pregnancy. TreatmentUpdate; 2001 Apr 19; 12(8):6-7. PubMed ID: 12132441 [No Abstract] [Full Text] [Related]
55. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. Wade NA, Unadkat JD, Huang S, Shapiro DE, Mathias A, Yasin S, Ciupak G, Watts DH, Delke I, Rathore M, Hitti J, Frenkel L, Samelson R, Smith ME, Mofenson L, Burchett SK. J Infect Dis; 2004 Dec 15; 190(12):2167-74. PubMed ID: 15551216 [Abstract] [Full Text] [Related]
56. Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection. Mateo MG, Gutierrez Mdel M, Vidal F, Domingo P. Expert Opin Drug Saf; 2012 May 15; 11(3):473-85. PubMed ID: 22468613 [Abstract] [Full Text] [Related]
57. Labeling changes for abacavir. AIDS Patient Care STDS; 2008 Aug 15; 22(8):683-4. PubMed ID: 18721055 [No Abstract] [Full Text] [Related]
58. Mitochondrial DNA and nucleoside toxicity. Rastegar DA. N Engl J Med; 2002 Jul 18; 347(3):216-8; author reply 216-8. PubMed ID: 12125710 [No Abstract] [Full Text] [Related]